Is Semaglutide a Game-changer for CKD? Insights for the Layperson Into the SMART Trial in the “Guide for Everyone”
The “ISN Global Kidney Trials Insights: A Guide for Everyone,” inspired by the ISN-ACT Global Trials Focus summaries, translates complex trial findings into accessible information. This initiative empowers people living with kidney disease and their caregivers to better understand advancements in kidney care.
Access all the simplified summaries here.
The latest case study features the SMART trial, which investigates whether semaglutide (Ozempic) — a medication commonly used for obesity and diabetes management — can protect kidney function and address related health challenges in people with chronic kidney disease (CKD) who do not have diabetes.
Access the SMART trial simplified summary here
By fostering dialogue between nephrologists and people living with kidney disease, including members of the Patient Liaison Advisory Group, this initiative enhances meaningful communication, strengthens advocacy efforts, and inspires greater participation in essential clinical trials.
Explore the Global Kidney Patient Organizations map here.
Read the Global Trials Focus summaries here.
